Amphastar at Wells Fargo conference: growth hinges on baqsimi, pipeline

Amphastar reaffirmed mid- to high-single-digit 2026 revenue growth and expects faster growth in 2027, supported by BAQSIMI, Primatene MIST and planned launches of AMP-004 insulin aspart and AMP-018 generic GLP-1. BAQSIMI's $250M-$275M peak-sales target depends on raising glucagon prescription penetration among insulin patients to 15%-16% from 12%; management expects 340B double-discounting issues to be mostly resolved in Q3 and fully resolved in Q4 2026. Near-term risks include BAQSIMI pricing pressure, underperforming AMP-007 revenue and an FDA warning letter at the IMS unit, although capex is being reallocated to modernize the facility without changing the overall spending plan.

Analysis

AMPH’s investable setup is a 2027 earnings-inflection debate rather than a near-term revenue-growth story. If the rebate-leakage remediation works, BAQSIMI’s incremental revenue should carry materially higher contribution margins than the company average, while insulin-aspart utilization of underused China API and pen capacity creates operating leverage that guidance likely does not fully capture. The key question is not prescription demand but whether gross-to-net improvement is durable and visible in 3Q/4Q results; management’s claimed recovery rate is consultant-derived rather than independently validated.

The IMS remediation is the underappreciated offset: warning letters frequently expand from release delays into supplemental FDA observations, consent-decree-like remediation costs, or delayed approvals if quality-system deficiencies prove systemic. Redirecting capex protects near-term cash spending, but it may defer capacity expansion and raises execution concentration at precisely the time AMPH needs clean regulatory inspections for its biosimilar launch cadence. A weak 3Q gross-margin recovery, incremental FDA correspondence, or any slip in the 2027 insulin-aspart filing/approval path would undermine the multiple-rerating thesis.

Consensus may be assigning too much value to the 2027 GLP-1 generic opportunity before knowing legal, supply, and competitor economics. Generic GLP-1 markets can be capacity-constrained but are also unusually exposed to patent settlements, branded supply normalization, and rapid price erosion; it should be treated as upside until product identity, filing status, and launch rights are disclosed. Conversely, AMPH’s complex-manufacturing capability could make its undisclosed biosimilar program more valuable than the market recognizes, but that is a 6-18 month optionality thesis, not a current earnings catalyst.

Key Decisions for Investors

• Maintain a 1-3 month watch-to-buy stance on AMPH rather than chase conference optimism. Initiate only after 3Q results demonstrate sequential BAQSIMI net-price/gross-margin recovery and reaffirm 2027 launch timing; target a 15-20% upside re-rating if EBITDA margins begin to reflect remediation, with a 10% stop or exit on evidence that gross-to-net remains elevated.
• For a catalyst position, buy a small AMPH equity position ahead of 3Q/4Q only if valuation remains discounted to specialty-generic peers on normalized free cash flow; size at half normal because FDA and launch-timing risk can gap the stock. Add after FDA inspection-status clarity, not on management assurances alone.
• Treat AMP-018 as non-underwritten upside. Set an alert for disclosure of the reference product, ANDA/legal status, manufacturing source, and expected launch window; without those data, a GLP-1-driven long thesis has insufficient visibility into price erosion and patent risk.
• Use LLY only as a monitoring proxy, not a hedge: BAQSIMI’s economics are now largely independent of Lilly, while insulin/GLP-1 competitive developments could affect AMPH’s future portfolio without being material to LLY. The cleaner risk control is position sizing and an FDA-warning-letter trigger.